Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: The PLATINO study

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 1, 2010, Pages 29-35

  Montes de Oca, Maria ^a   Perez Padilla, Rogelio ^b   Tálamo, Carlos ^a   Halbert, Ronald J ^c   Moreno, Dolores ^a   Lopez, Maria Victorina ^d   Muiño, Adriana ^d   José Roberto, B Jardim ^e   Valdivia, Gonzalo ^f   Pertuzé, Julio ^f   Ana Maria, B Menezes ^g  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^b Institute of Respiratory Diseases   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^g FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Epidemiology asthma COPD; Prevalence

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GOLD STANDARD; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; TREATMENT RESPONSE;

AGED; BRONCHI; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 75049084048     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.09.005     Document Type: Article

References (23)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
2. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 1543-1554
3. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 144 (1991) 1202-1228
4. Pellegrino R., Viegi G., Brusasco V., Crapo R.O., Burgos F., Casaburi R., et al. Interpretative strategies for lung function tests. Eur Respir J 26 (2005) 948-968
5. Anthonisen N.R., and Wright E.C. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 133 (1986) 814-819
6. Criteria for the assessment of reversibility in airways obstruction. Report of the committee on emphysema, American college of chest physicians. Chest 65 (1974) 552-553
7. Eliasson O., and Degraff Jr. A.C. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis 132 (1985) 858-864
8. Brand P.L., Quanjer P.H., Postma D.S., Kerstjens H.A., Koëter G.H., Dekhuijzen P.N., et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch chronic non-specific lung disease (CNSLD) study group. Thorax 47 (1992) 429-436
9. Calverley P.M., Burge P.S., Spencer S., Anderson J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 (2003) 659-664
10. Donohue J.F. Minimal clinically important differences in COPD lung function. COPD 2 (2005) 111-124
11. Menezes A.M., Victora C.G., Perez-Padilla R., and PLATINO Team. The Platino project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities. BMC Med Res Methodol 4 (2004) 15
12. Menezes A.M., Perez-Padilla R., Jardim J.R., Muiño A., Lopez M.V., Valdivia G., et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366 (2005) 1875-1881
13. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med 152 (1995) 1107-1136
14. Hankinson J.L., Odencrantz J.R., and Fedan K.B. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159 (1999) 179-187
15. Pérez-Padilla R., Valdivia G., Muiño A., López M.V., Márquez M.N., Montes de Oca M., et al. Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over. Arch Bronconeumol 42 (2006) 317-325
16. Chhabra S.K. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma 42 (2005) 367-372
17. Kesten S., and Rebuck A.S. Is the short-term response to inhaled β-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?. Chest 105 (1994) 1042-1045
18. Newton M.F., O'Donnell D.E., and Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 121 (2002) 1042-1050
19. Cerveri I., Pellegrino R., Dore R., Corsico A., Fulgoni P., van de Woestijne K.P., et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 88 (2000) 1989-1995
20. Ben Saad H., Préfaut C., Tabka Z., Zbidi A., and Hayot M. The forgotten message from GOLD: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther 21 (2008) 767-773
21. O'Donnell D.E., Forkert L., and Webb K.A. Evaluation of bronchodilator responses in patients with "irreversible" emphysema. Eur Respir J 18 (2001) 914-920
22. Girard W.M., and Light R.W. Should the FVC be considered in evaluating response to bronchodilator?. Chest 84 (1983) 87-89
23. Anthonisen N.R., Lindgren P.G., Tashkin D.P., Kanner R.E., Scanlon P.D., and Connett J.E. Bronchodilator response in the lung health study over 11yrs. Eur Respir J 6 (2005) 45-51